Thorsten von Goessel
Thorsten von Gossel of Engineering & Facilities, describes Boehringer Ingelheim as family business with long-term perspective and wonderful leadership team.
Search
Liliana Montano
Liliana Montano works as a scientist within the Global Innovation and Alliance Management and talks about her journey at Boehringer Ingelheim.
Internal application
Internal applications | FAQ
Simon Heinrich
Simon Heinrich, an automation engineer in the Engineering and Facilities department, provides an in-depth look at working life at Boehringer Ingelheim.
Venu Thatikonda
An in-depth look into working life at Boehringer Ingelheim with Venu Thatikonda.
Corporate profile
Corporate profile
OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)
OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)
Bovine
Bovine
Therapeutics
Science and Innovation - Animal Health Innovation - Therapeutics
Vaccines
Science and Innovation - Animal Health Innovation - Vaccines
Strategies for overcoming resistance in parasites
Strategies for overcoming resistance in parasites
The Hidden Cost of Parasites in Cattle
The Hidden Cost of Parasites in Cattle
How do you know if your cattle have parasites?
How do you know if your cattle have parasites?
What we do
Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Alberta’s Dr. Karen Schwartzkopf-Genswein named 2022 Metacam® 20 Bovine Welfare Award winner
Award recognizes outstanding contributions to the welfare of animals in Canada
Stefanie Bock Kreilinger
Stefanie Bock-Kreilinger works in the legal department at Boehringer Ingelheim as head of corporate legal medicine, evidence and digital health.
Who are we?
Started in 1885 by Albert Boehringer, this independent family-owned company has grown into a top contributor in Human Pharma and Animal Health.
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
• Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® • R&D investments of 5 billion EUR, or 21 percent of net sales • Net sales rise 10.5 percent (currency adjusted), up strongly to 24.1 billion EUR
Ryan Henri Rickards
Ryan Henry Rickards, a senior finance manager for US Animal Health Commercial Controlling team, highlights his career at Boehringer Ingelheim.
Andreas Lenk
Andreas Lenk, Head of Legal and Compliance Germany, discusses his role supporting human pharma and animal health business in legal and compliance matters.
EQVALAN® GOLD
EQVALAN® GOLD
Legal Notices
Legal Notices
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales) More than 25 billion EUR investment in R&D and 7 billion EUR in capital expenditure over the next five years Human Pharma pipeline acceleration: up to 15 new product launches
Managing and treating equine osteoarthritis
Managing and treating equine osteoarthritis
Managing calf pain during disbudding and dehorning
Managing calf pain during disbudding and dehorning